Combined phenotype/genotype datasets. These are (with some good reason) very difficult for anyone outside the medical-research establishment to get access to, but the net result is that it creates market barriers supporting the existing big players.
I understand pharma not sharing but much of the hospital/broad/university data is produced with (at least some) public money.